{"id":98101,"title":"Novacyt S.A. (AIM:NCYT) DHSC dispute update","publisher":"Share Talk","author":"sharetalk","published":"2022-06-16T07:59:25+00:00","modified":"2022-06-16T07:59:25+00:00","canonical_url":"https://www.share-talk.com/novacyt-s-a-aimncyt-dhsc-dispute-update-2/","markdown_url":"https://www.share-talk.com/novacyt-s-a-aimncyt-dhsc-dispute-update-2.md","json_url":"https://www.share-talk.com/novacyt-s-a-aimncyt-dhsc-dispute-update-2.json","category":"Healthcare","categories":["Healthcare","Pharmaceutical"],"tags":["Clarence Jaccard-Briat","development","diagnostic","diagnostics","families","Graham Mullis","haematology","IT-IS","IT-IS International Ltd","Lab21","Lab21 Products","microbiology","molecular","NCYT","NHS England","Novacyt","Novacyt S.A.","Primerdesign","product","Roderic Fuerst","SARS-CoV-21","serology","serology markets","Share Talk","SNPsig","UNICEF","vitro","VoC Framework"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&ssl=1","format":"news","language":"en-GB","content":"Paris, France and Camberley, UK – 16 June 2022 – **Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT),** an international specialist in clinical diagnostics, announces an update on its ongoing dispute with the Department of Health and Social Care (“DHSC”).\n\nOn 25 April 2022, the Company was notified that the DHSC had issued a claim against Primerdesign Ltd and Novacyt S.A. for £134.6m in relation to the contract dispute announced by the Company on 9 April 2021 regarding its second supply contract with the DHSC, announced on 29 September 2020.\n\nOn 15 June 2022, the Company filed a defence of the claim received on 25 April 2022 and a counterclaim of £81.5m against the DHSC. The value of the counterclaim is broadly in line with the amounts previously announced by the Company in its full year 2020 results, plus related interest.\n\nThe Company continues to believe it has strong grounds to defend the claim and assert its contractual rights, including recovering outstanding sums due from the DHSC under the counterclaim.\n\nUnfortunately, the Company is unable to provide further comment at this time but will provide further updates as appropriate and to the extent permitted to do so.\n\nThe information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under Article 7 of the Market Abuse Regulation (EU) No. 596/2014 (as amended) as it forms part of the domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (as amended). Upon the publication of this Announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\n\nContacts\n\n**Novacyt SA**\n\n**David Allmond, Chief Executive Officer**\n\n**James McCarthy, Chief Financial Officer**\n\n**+44 (0)1276 600081**"}